Artículos de revistas
Naringin Inhibits Tumor Growth and Reduces Interleukin-6 and Tumor Necrosis Factor alpha Levels in Rats with Walker 256 Carcinosarcoma
Registro en:
Anticancer Research. Int Inst Anticancer Research, v.32, n.1, p.129-133, 2012
0250-7005
WOS:000298780900016
Autor
Camargo, Camila A.
Gomes-Marcondes, Maria Cristina C.
Wutzki, Nathalie C.
Aoyama, Hiroshi
Institución
Resumen
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) The flavonoid naringin is a polyphenolic compound that naturally occurs in citrus. Patients with cancer generally present features of malnutrition and cachexia. Levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are raised in patients with cancer. This study was designed to analyze the in vivo effect of naringin in the therapeutic treatment of rats bearing Walker 256 carcinosarcoma (W256). Rats were treated intraperitoneally with different doses of naringin (10, 25 and 35 mg/kg), for 50 days. At 25 mg/kg, naringin inhibited tumor growth by similar to 75%. With this treatment, TNF-alpha and IL-6 levels decreased (p<0.05) in comparison with the control. In addition, two rats presented complete tumor regression. Inhibition of tumor growth, survival increase and the reduction of TNF-alpha and IL-6 levels in rats bearing W256 treated with naringin strongly suggest that this compound has potential as an anticarcinogenic drug. 32 1 129 133 Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Fundo de Apoio ao Ensino Pesquisa e a Extensao/UNICAMP Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)